Lessons Learned: Peripheral Neuropathy with Cancer

When trying to cope with peripheral neuropathy, sufferers could benefit from others’ success.

PUBLISHED: 1:00 AM, SUN JUNE 15, 2014
Talk about this article with other patients, caregivers, and advocates in the General Discussions CURE discussion group.
Since 2005, Linda McIntosh, a retired nurse in Groton, Conn., has been living with Waldenström macroglobulinemia, a rare form of non-Hodgkin lymphoma. She received the diagnosis at age 58, and chemotherapy has kept the cancer at bay for nearly a decade, but she says the most challenging aspect of her experience has been coping with nerve damage called neuropathy, the numbness and pain in her hands and feet that one study indicated is a symptom in around 45 percent of those who receive a diagnosis of Waldenström. For McIntosh, neuropathy has become her constant companion.

“The person who diagnosed it as neuropathy said, ‘You’ve got neuropathy, live with it.’ ”

Statistics indicate that up to 90 percent of patients who receive nerve-damaging chemotherapy agents may experience neuropathy, though the exact figure is unknown because there can be numerous inciting factors.

Many hear a response similar to the one McIntosh received from her healthcare team, due to the lack of information and treatment. For example, nerve damage can be a symptom of the cancer itself, as in McIntosh’s case, or a side effect of cancer treatment, including chemotherapy and radiation—with drug-induced causes now representing a growing percentage of cases.

[Find information and support with CURE-selected resources]

Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting side effect of certain classes of chemotherapy drugs, including platinumbased drugs, taxanes, vinca and plant alkaloids, certain immunomodulating agents and others. How these drugs affect the nerves differs, depending on the amount of the drug used, the treatment schedule, the patient’s age and pre-existing issues that can put the patient at risk.

My job is to figure out the cause. There is often

a reason why one patient gets severe symptoms from

chemotherapy and another doesn't."

CIPN affects the peripheral nerves, which include the sensory, motor and autonomic nerves. Symptoms of sensory nerve damage include numbness, tingling, temperature sensitivity, tightness and pain in the feet and hands. Motor nerve damage may result in foot drop and muscle weakness, affecting patients’ balance and ability to carry items. Autonomic nerves regulate involuntary body functions such as heartbeat, blood flow, breathing and digestion, and when they are involved, the result can be diarrhea, constipation, urine retention, impotence or unstable blood pressure upon standing, which can lead to dizziness and falling.

One challenge is insufficient information to help identify which patients are at risk for developing neuropathy with specific drugs and why. This spring, the American Society of Clinical Oncology released clinical practice guidelines for CIPN, which referred to the lack of high-quality evidence for any treatment to prevent CIPN while confirming the variations in severity, depending on regimens, duration of exposure and assessment methods.

Talk about this article with other patients, caregivers, and advocates in the General Discussions CURE discussion group.
Special Feature
Share Your Art
Related Articles
Pairing Radiation Oncology and Palliative Care Leads to Better Outcomes
A novel service model allowed for shorter durations of treatment with radiation, fewer unfinished treatments with radiation, shorter hospital stays and increased use of palliative care.
Varubi Represents 'Another Tool in the Toolbox' for CINV
The approval of Varubi was based on data from several phase 3 trials of the agent in more than 2,500 patients receiving various emetogenic chemotherapy agents.
Acupuncture Could Cool Hot Flashes in Breast Cancer Survivors
Electroacupuncture produced larger placebo and smaller nocebo effects than did gabapentin for treating hot flashes among breast cancer survivors.
Related Videos
Sharon L. Bober on Sexual Health Changes in Relation to Treatment
Sharon L. Bober, director, Sexual Health Program, Dana-Farber Cancer Institute, discusses changes in sexual health as they relate to different treatments for cancer.
Hope Rugo on Managing Sexual Dysfunction From Ovarian Suppression
Hope S. Rugo discusses managing sexual dysfunction from ovarian suppression treatment for breast cancer.
Hope Rugo on Managing Effects From Ovarian Suppression in Patients With Breast Cancer
Hope S. Rugo discusses managing effects from ovarian suppression treatment for breast cancer.